Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruxolitinib - Incyte Corporation/Novartis

Drug Profile

Ruxolitinib - Incyte Corporation/Novartis

Alternative Names: INC-424; INCB 018424 phosphate; INCB-018424; INCB-18424; Jakafi; Jakavi; RUX; ruxolitinib phosphate

Latest Information Update: 12 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Baylor Breast Care Center; Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Lymphoma Academic Research Organisation; Massachusetts General Hospital; Novartis; RWTH Aachen University; Sunnybrook Health Sciences Centre; Tufts-New England Medical Center; University Health Network of Toronto; University of Cologne; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antianaemics; Antibronchitics; Antihaemorrhagics; Antineoplastics; Antipsoriatics; Antirheumatics; Cyclopentanes; Nitriles; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Pancreatic cancer; Polycythaemia vera; Essential thrombocythaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Graft-versus-host disease; Myelofibrosis; Polycythaemia vera
  • Phase III Atopic dermatitis; Essential thrombocythaemia; Vitiligo
  • Phase II Alopecia areata; Breast cancer; Breast disorders; Bronchiolitis obliterans; Cachexia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Head and neck cancer; Hodgkin's disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Thalassaemia
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma
  • No development reported Psoriasis
  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 07 Dec 2019 Pharmacodynamics data from preclinical studies in Haematological disorders presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
  • 28 Nov 2019 No recent reports of development identified for clinical-Phase-Unknown development in Polycythaemia-vera(In children, In the elderly, In adults) in USA (PO, Tablet)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy) in Austria (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top